Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-D in cancer-associated venous thromboembolism
ISRCTN86712308Phase 3Completed
- Sponsor
- University of Warwick
- Start
- May 2013
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE) and 1 more comparing Rivaroxaban with Dalteparin (2 arms). Primary endpoint: VTE recurrence rates. Started May 2013; status: completed.
02
Drugs
rivaroxabandalteparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)cancer-associated thrombosis (CAT)
Beyond the preview
Go deeper on ISRCTN86712308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86712308.